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The allogeneic hematopoietic stem cell transplantation procedure—the only curative
therapy for many types of hematological cancers—is increasing, and graft vs. host
disease (GVHD) is the main cause of morbidity and mortality after transplantation.
Currently, GVHD diagnosis is clinically performed. Whereas, biomarker panels have been
developed for acute GVHD (aGVHD), there is a lack of information about the chronic form
(cGVHD). Using nuclear magnetic resonance (NMR) and gas chromatography coupled
to time-of-flight (GC-TOF) mass spectrometry, this study prospectively evaluated the
serummetabolome of 18 Brazilian patients who had undergone allogeneic hematopoietic
stem cell transplantation (HSCT). We identified and quantified 63 metabolites and
performed the metabolomic profile on day −10, day 0, day +10 and day +100,
in reference to day of transplantation. Patients did not present aGVHD or cGVHD
clinical symptoms at sampling times. From 18 patients analyzed, 6 developed cGVHD.
The branched-chain amino acids (BCAAs) leucine and isoleucine were reduced and
the sulfur-containing metabolite (cystine) was increased at day +10 and day +100.
The area under receiver operating characteristics (ROC) curves was higher than 0.79.
BCAA findings were validated by liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS) in 49 North American patients at day +100; however, cystine
findings were not statistically significant in this patient set. Our results highlight the
importance of multi-temporal and multivariate biomarker panels for predicting and
understanding cGVHD.
Keywords: graft vs. host disease, bone marrow transplantation, cancer, metabolomics, branched chain amino
acids, biomarkers, mass spectrometry, nuclear magnetic resonance
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is
the only curative therapy available for several hematological
malignances (1). Despite the improvements in survival following
allogeneic HSCT, chronic graft vs. host disease (cGVHD) remains
the most important cause of morbidity and late mortality for
long-term transplant survivors (2–5). cGVHD is a multisystem
disorder with alloreactive T cells (5), dendritic cells (DC) (6) and
donor B cells (7) implicated in the pathogenesis. Although risk
factors are associated with cGVHD incidence (patient age, MHC
compatibility, female donor to male patient), the diagnosis relies
almost entirely on the presence of clinical symptoms, generally
in a stage with high grade inflammatory infiltrates and target
organ damage (8, 9). Currently, no laboratory or molecular tests
exist for cGVHD prediction prior to symptom development (10).
For cGVHD, few groups have reported potential biomarkers and
a panel has not been developed as for aGVHD (11). In 2007,
high levels of B-Cell Activation Factor were observed in patients
with active cGVHD (12), and in 2014 the protein CXCL9, a
T-cell chemoattractant, was identified as a potential biomarker
for the onset of newly diagnosed cGVHD in patients (2).
Both protein concentrations were measured in plasma samples
through hypothesis-driven projects for cGVHD diagnosis. Other
inflammatory and regulatory proteins may also be associated
with an increased risk for cGVHD, such as higher levels of TNFa
and IL-10 (13, 14) and decreased TGFb (14, 15) and IL-15 (16).
Impressive progress has been made in “Omics” sciences;
metabolomics analyses—complementary to genomic,
transcriptomic, and proteomic—are capable of producing a
more detailed and systematic picture of cellular processes and
their response to changes in the environment. This dynamic
nature is not always represented by only one biomarker, but by
biomarker signatures, that increase the sensitivity and specificity
required by clinical diagnosis (17). Toward this end, the
NMR (nuclear magnetic resonance)- and mass-spectrometry-
based metabolomics approaches enable the detection and
absolute quantification of dozens of metabolites (e.g., amino
acids, carbohydrates, fatty acids, keto acids) simultaneously,
in a hypothesis-free approach, a very important feature for
biomarker discovery studies (18). The interaction between
genetic factors (e.g., mutations, epigenetic, single nucleotide
polymorphisms) and lifestyle factors (age, diet, exercise, drugs,
hormonal homeostasis, health-to-disease status, gut microbiota)
will affect the pool of metabolites in a given biofluid at a given
timepoint (19–21), allowing the use of metabolomic data for
multivariate analysis and modeling in pathology studies.
However, to date, only a few reports have been published
exploring metabolomics in studies involving HSCT. One study
in animal models implicates glutathione dysregulation in an
experimental GVHD model and branched chain amino acids
(BCAA) with hepatic injury (22). Another study analyzed
pretransplant the metabolic profiles of patients who had
undergone HSCT implicated BCAA, among other metabolites,
to the risk of developing acute GVHD (23). In the present work,
multi-platform metabolomics facilities profiled blood serum
prospectively collected (day −10 to day +100) in a Brazilian
cohort, creating a panel with potential biomarkers predictive
for cGVHD. This panel was further validated in plasma from a
North American cohort (day +100). Our results demonstrated
that BCAAs are potential prediction biomarkers for cGVHD in
both cohorts, and sulfur-containing metabolites (precursors of
GSH) could also be implicated in the pathology.
PATIENTS AND METHODS
The outline of the methodology is shown in Figure 1. Briefly,
blood samples were collected from patients who were recipients
first of HSCT, and who did not develop aGVHD or present
clinical symptoms of cGVHD at collection time. The blood
serum samples from the discovery cohort were collected in four
different periods of HSCT (at day −10, 0, +10, and +100)
from 18 Brazilian patients, and the samples from day +100
of validation cohort were obtained from 49 North American
patients. For discovery cohort, metabolites were identified and
absolute quantification was determined by nuclear magnetic
resonance (NMR) (24, 25) and the measurements were also
verified by gas chromatography coupled to mass spectrometry
(GC-MS) (26–28). After follow-up, patients were divided into
2 groups—patients that developed cGVHD and patients that
did not develop cGVHD (cGVHD-free) (29)—and uni- and
multivariate statistical analyses were performed. Results from
the discovery cohort were validated by relative quantification of
metabolites by liquid-chromatography coupled to tandem mass
spectrometry (LC-MS/MS) (30, 31) in the validation cohort.
Patients and Sample Collecting
This study included a prospective, nested cohort of 41 adult
Brazilian patients who had undergone first full-match (related
donor) allogeneic HSCT at the BMT Unit of the Clinical
Hospital/University of Campinas between August 2011 and
January 2013. All patients signed the Consent Form approved by
the School of Medicine Institutional Review Board (n.1062/2010)
of the University of Campinas, Brazil. Serum samples were
prospectively collected in four different periods of the HSCT:
on the day of hospitalization, D-10 (average day −7, min
−12, max −5), on the day of transplantation, D0 (average
day 0, min 0, max 0), during the neutropenic period, D+10
(average day 10, min 7, max 14), and D+100 (average day 99,
min 75, max 126) post-HSCT (Figure 1). Blood samples were
collected in serum clot activator with gel separator tubes after
an overnight fast. These samples were centrifuged 10min, 3,000
rpm at room temperature, aliquoted and immediately stored at
−80◦C until analyses by nuclear magnetic resonance (NMR)
and gas chromatography coupled with time-of-flight (GC-TOF)
mass spectrometry.
Findings from the Brazilian cohort were examined in a
validation cohort of 49 North Americans who had undergone
allogeneic HSCT between January 2004 and January 2013. Blood
plasma samples from D+100 (average day 98, min 81, max
120) post-HSCT were selected from a sample bank of HSCT
patients at the Dana-Farber Cancer Institute (Boston, MA). At
the time of blood collection, none of the patients had clinical
symptoms of cGVHD or had developed aGVHD. After the
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FIGURE 1 | Experimental design. The approach involves the targeted serum metabolic profiling (by NMR and GC-MS) of Brazilian patients undergoing allogeneic
hematopoietic stem cell transplantation (discovery cohort). Blood serum samples were prospectively collected the day before starting the myeloablative conditioning
regimen (D-10), HSCT day (D0), as well as 10 and 100 days after HSCT (D+10 and D+100, respectively). The retro-prospective statistical analysis (uni- and
multivariate) aimed to create a panel of potential biomarkers for cGVHD. This panel was further validated in North American patients’ plasma collected at day +100 by
targeted metabolic profiling LC-MS/MS. Any patients showed aGVHD or cGVHD symptoms before or at sampling day.
blood collection, 25 patients developed cGVHD and 24 were
cGVHD-free. Written informed consent was obtained from each
patient and donor prior to sample collection, in accordance
with the Declaration of Helsinki. Protocol approval was obtained
from the Human Subjects Protection Committee of the Dana-
Farber/Harvard Cancer Center. Samples from the validation
cohort were prepared and analyzed by liquid chromatography
coupled to tandem mass spectrometry (LC-MS/MS) (Figure 1).
Metabolite Profiling Analyses by Nuclear
Magnetic Resonance (NMR)
Samples from the discovery cohort were defrosted on ice. In
order to remove proteins and insoluble impurities, samples were
filtered in a 3 kDa cut-off filter (Millipore Microcron YM3)
rinsed 4 times with water prior to use to remove the glycerol
content from the membrane. The filtration was performed by
centrifugation at 11,000 rpm, 4◦C for 1 h. The filtered samples
were diluted 3x in a final concentration of 100mM phosphate
buffer, with pH 7.4, 10% D2O and referenced with 0.5mM DSS
(4,4-dimethyl-4-silapentane-1-sulfonic acid) for further absolute
quantification of metabolites (24). The samples (550 µL) were
transferred to 5mm NMR tubes (Norell R© Standard SeriesTM)
for analysis.
The acquisition of spectra was performed on an
Agilent/Varian INOVA600 spectrometer operating at 1H
Larmor frequency of 599.887 MHz and temperature of 298K.
The spectrometer was equipped with a triple resonance cryogenic
probe and a Z pulse-field gradient unit. 1D pre-saturation pulse
sequence was collected with 256 transients and 4 steady-state
scans using a 4 s acquisition time and a 1.5 s recycle delay.
Before the processing and spectra analyses, all FIDs were
zero-filled to 64 k data points and subjected to line broadening
of 0.5Hz. The internal standard for chemical shift referencing
(set to 0 ppm) and quantification was DSS’s singlet. The spectra
processing, identification and quantification of metabolites
were performed by using the application package Chenomx
NMR Suite and the target profiling approach (Chenomx Inc.),
as previously described (25). All identified and quantified
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metabolite concentration information was exported from the
spectra to an excel sheet. All metabolite concentrations, except
for DSS, were multiplied by 3 in order to adjust for the
dilution effect.




For metabolite extraction, 100 µL of serum from the discovery
cohort was mixed with 1mL of a precooled (−15◦C) mixture
of MTBE: methanol:water 3:1:1 (v/v/v), shaken for 30min
at 4◦C and ultrasonicated for 10min in an ice-cooled bath,
as described previously. Three phases were obtained after
the addition of methanol:water (3:1) and centrifugation for
5min at 4◦C (26). The 250 µl of the aqueous phase (middle
phase) was dried and derivatized as described by Roessner
et al. (27). One microliter of the derivatized samples were
analyzed on a Combi-PAL autosampler (Agilent Technologies
GmbH, Waldbronn, Germany) coupled to an Agilent 7890
gas chromatograph coupled to a Leco Pegasus 2 time-of-
flight mass spectrometer (LECO, St. Joseph, MI, USA) as
described by Weckwerth (32). QC (mix of 20 standards)
and blank samples were included in the running queue
after every 10 samples, and data was normalized by total
ion counting. Additionally, internal standard (C13 sorbitol)
was spiked during sample extraction to control extraction
performance and for estimation of metabolite recovery.
Chromatograms were exported from Leco ChromaTOF
software (version 3.25) to R software. Peak detection, retention
time alignment, and library matching were performed using
Target Search R-package (28). Metabolites were quantified
by peak intensity of a selective mass. Metabolite intensities
were normalized by dividing by the sum of the total
ion count.
Polar Metabolite Profiling Analyses by
Liquid Chromatography Coupled to
Tandem Mass Spectrometry (LC-MS/MS)
Plasma metabolic profiling from the validation cohort was
performed as described previously (30, 31). Briefly, polar
metabolites were extracted from 10 µL of blood plasma via
protein precipitation with nine additions of nine 74.9:24.9:0.2
vol/vol/vol acetonitrile/methanol/formic acid containing two
additional stable isotope-labeled internal standards for valine-d8
and phenylalanine-d8. Samples were centrifuged (10min, 15,000
g, 4◦C) and the supernatants were injected directly. Liquid
chromatography-tandem mass spectrometry data were acquired
in a 4000 QTRAP triple quadrupole mass spectrometer (Applied
Biosystem/Sciex). Hydrophilic interaction chromatography
(HILIC, 150 × 2.1mm Atlantis HILIC columns, Waters) was
performed. MS analyses were carried out using electrospray
ionization (ESI) and multiple reaction monitoring (MRM)
scans in the positive ion mode. MultiQuant software (Version
1.1; Applied Biosystems/Sciex) was used for automated peak
integration and metabolite peaks were manually reviewed for
quality of integration.
Cystine and Cysteine Measurements by
Liquid Chromatography Coupled to
Tandem Mass Spectrometry (LC-MS/MS)
For cystine and cysteine measurements in the validation cohort
blood plasma deproteination was performed by ultrafiltration
in a 3 kDa cut-off filter (Millipore Microcron YM3) previously
rinsed 4 times with water to remove the glycerol content from the
membrane. Ten microliters of filtered plasma was diluted in nine
volumes of solution A (1:1 water+ 0.1% formic acid: acetonitrile
+ 0.1% formic acid, 55.55µM cystine-d4, 55.55µM cysteine-
d2, 0.21µg/mL phenylalanine-d8) and injected directly. Liquid
chromatography-tandem mass spectrometry (LC-MS) data were
acquired using an Agilent 6490 Triple Quadrupole LC/MS/MS
coupled to 1290 Infinity UHPLC. The two pumps were similarly
configured for hydrophillic interaction chromatography (HILIC)
using 150 × 2.1mm Atlantis HILIC columns (Waters) and with
the same mobile phases (mobile phase A: 10mM ammonium
formate and 0.1% formic acid, v/v; mobile phase B: acetonitrile
with 0.1% formic acid, v/v). Each column was eluted isocratically
with 5% mobile phase A for 1min followed by a linear
gradient to 60% mobile phase A over 10min. MS analyses were
carried out using electrospray ionization (ESI) and multiple
reaction monitoring (MRM) scans in the positive ion mode.
Declustering potentials and collision energies were optimized
for each metabolite by infusion of reference standards prior to
sample analyses. The dwell time for each transition was 30ms,
the ion spray voltage was 4.5 kV, and the source temperature
was 425◦C. Internal standard peak areas were monitored for
quality control and individual samples with peak areas differing
from the group mean by more than two standard deviations
were re-analyzed. Analyst software was used for automated peak
integration and metabolite peaks were manually reviewed for
quality of integration and compared against a known standard
to confirm identity.
Statistical Analyses
For the screening cohort (Brazilian patients), the statistical
study included patients whose blood samples were collected
throughout all periods of the study (day −10, day 0, day +10
and day +100, relative to HSCT day). Patients who had at
least one missing sample, patients who died for reasons other
than cGVHD and patients who developed aGVHD anytime
or cGVHD at any sampling time, were excluded from the
statistical analysis. The statistical analyses aimed to compare the
metabolic differences between patients who developed cGVHD
after blood collection and patients with no cGVHD diagnoses
(cGVHD-free) during follow up. In order to obtain significant
predictors for cGVHD, cases and controls were compared by
univariate and multivariate analysis. The independent variable
was set as cGVHD-free or cGVHD group (29). Only data
with normal distributions (Shapiro-Wilk normality test) were
analyzed by t-test with no further normalization. Student’s t-
test followed by hierarchical clustering method and Heatmap
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visualization were applied. For Heatmap visualization, data were
autoscaled. The distance measurement was Euclidean and the
clustering algorithm was Ward. The best clustering result, for
cGVHD-free vs. cGVHD groups, was selected with the minimum
metabolites possible. Area under curve (AUC) from univariate
andmultivariate receiver operating characteristic (ROC) analyses
and corresponding 95% confidence intervals were calculated
to estimate the clinical potential of the selected metabolites as
prognostic cGVHD biomarkers (18). The statistical analyses were
performed using the software Prism 6.0f (GraphPad Software,
Inc.) and the web tools MetaboAnalyst 2.0 and ROCCET (18, 33).
The validation of results was performed in 49 North-American
patients (24 cGVHD-free and 25 cGVHD) with plasma samples
collected around day +100 by univariate analysis (student t-
test) and ROC curve analyses. Statistical analyses correlating data
from different platforms (NRM, GC-MS and LC-MS/MS) were
not performed.
RESULTS
We hypothesized that changes in the metabolic profile of blood
precede cGVHD’s clinical symptoms. Using a discovery cohort
(Brazilians), we performed metabolomic profiling on serum
blood collected on days −10, 0, +10, and +100, referred
by HSCT day (Figure 1). From 41 adult patients who had
undergone first fully-matched related donor allogeneic HSCT
between August 2011 and January 2013, 18 (44%) patients were
enrolled on this study. None of these patients presented with
cGVHD or aGVHD symptoms at or before the day of collection.
Patient median age was 36 years (21–69 years), 8 patients (44%)
were female and 5 (28%) were male receptors from female
donors. Six (33%) patients developed cGVHD and 12 (67%)
patients were cGVHD-free.(29) The median time of cGVHD
diagnosis was 179 days (124–246 days) and the follow-up median
was 459 days (156–679 days). Characteristics of the study
population are shown on Table 1. Sixty-three (63) metabolites
were identified and quantified in serum blood samples of
these patients by the NMR-based metabolomic platform
(Supplementary Table 1).
The concentration of sulfur-containing metabolite cystine
was found higher in cGVHD patients at day +10 (63.8 ±
5.4µM) and day +100 (83.5 ± 7.2µM) when compared to
cGVHD-free patients at day +10 (35.6 ± 5.2µM) and day
+100 (64.9 ± 3.7µM), with student t-test p = 0.004 (day +10)
and p = 0.021 (day +100) (Figure 2A). In contrast to cystine,
branched chain amino acids displayed reduced concentrations in
the cGVHD group when compared to the cGVHD-free group
(Figures 2B–D). Leucine concentrations (Figure 2B) were lower
in patients that developed cGVHD at day +10 (111.6 ± 6.8µM
vs. 134.4 ± 6.5µM cGVHD vs. cGVHD free patients, p =
0.045) and day +100 (99.2 ± 6.1µM vs. 121.8 ± 5.5µM, p
= 0.023). Isoleucine concentrations (Figure 2C) were lower in
cGVHD patients at day +100 (58.0 ± 5.2µM) than in cGVHD-
free patients (74.4 ± 3.8µM), p = 0.023. The concentration of
valine (Figure 2D) also tended to be lower in cGVHD patients.
BCAA and cystine concentrations were verified by GC-MS
TABLE 1 | Demographic and characteristics of discovery cohort (Brazilians).
Characteristics Total (n = 18) cGVHD-Free (n = 12) cGVHD (n = 6)
Patient age, median
(range), y
36 (21–69) 35 (21–61) 47 (34–69)
Patient gender, no. (%)
Female 8 (44) 6 (50) 2 (33)
Diagnosis at transplant, no. (%)
Acute myeloid leukemia 9 (50) 8 (67) 1 (17)
Chronic myeloid
leukemia
1 (6) 1 (8) 0 (0)
Non-malignant
Disorders
2 (11) 0 (0) 2 (33)
Others 6 (34) 3 (25) 3 (50)
Donor age, median
(range), y
38 (19–69) 38 (26–58) 47 (19–69)
Receptor/Donor gender, no. (%)
Male/female 5 (28) 3 (25) 2 (33)
Others 13 (72) 8 (67) 4 (67)
Donor type, no. (%)
HLA-identical related 18 (100) 12 (100) 6 (100)
Conditioning regimen types, no. of Patients (%)
Busulfan and
Cyclophosphamide
11 (61) 8 (67) 3 (50)
Busulfan and
Fludarabine
2 (11) 1 (8) 1 (17)
Fludarabine and TBI 2 (11) 0 (0) 2 (33)
Other 3 (17) 3 (25) 0 (0)
Source of stem cells, no. of Patients (%)
Bone marrow 8 (44) 6 (50) 2 (33)
Peripheral blood 10 (56) 6 (50) 4 (67)
GVHD prophylaxis, no. of Patients (%)
Cyclosporine+
Methotrexate
16 (89) 12 (100) 4 (67)
Cyclosporine+
Mycophenolate mofetil
2 (11) 0 (0) 2 (33)
(Supplementary Figure 1, in arbitrary units) and were in good
agreement with NMR measurements, except for cystine.
The variables identified by the t-test (cystine day +10,
cystine day +100, leucine day +10, leucine day +100 and
isoleucine day +100) were subject to hierarchical clustering
analysis to generate a heatmap in order to investigate group
segregation. As shown in Figure 3A, these variables were
able to cluster cGVHD patients from cGVHD-free patients.
Principal component analyses (PCA, Supplementary Figure 2A)
displayed different segregation patterns for cGVHD patients
and cGVHD-free patients by using 2 principal components
(PC). PC1 explained 47.1% of variance and PC2 explained
29.3%. Partial least squares Discriminant Analysis (PLS-DA,
Supplementary Figure 2B) also discriminates both groups (PC1
41.7% and PC2 34.4%, accuracy 0.889, R2 0.81 and Q2 0.69, 2000
permutation test p= 0.022).
ROC curve analyses were performed to better assess the
clinical utility of each metabolite (as individual or composite)
for cGVHD prediction (Figures 3B–G). All area under curve
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FIGURE 2 | Branched chain amino acids (BCAAs) are reduced and the sulfur-containing metabolite cystine is increased in patients prone to developing cGVHD.
Concentration dynamics of potential predictive cGVHD biomarkers along allogeneic HSCT in the discovery group. From 63 metabolites measured by NMR at blood
serum, 3 displayed concentration patterns important for differentiating cGVHD patients from patients without cGVHD by hierarchical clustering analyses (HCA). Valine
concentration is included because it is a branched chain amino acid (as leucine and isoleucine). The day before starting the myeloablative conditioning regimen is
represented by D-10, D0 is the HSCT day, D+10 and D +100 are 10 and 100 days after HSCT. (A) Cystine, (B) Leucine, (C) Isoleucine, (D) Valine. Bars: standard
error mean. Asterisk: student’s t-test p < 0.05.
(AUC) measurements generated were higher than 0.76. Cystine
at day +10 resulted in the best curve (Figure 3B, AUC 0.944,
CI 0.792–1, p = 0.004), followed by leucine at day + 100
(Figure 3C, AUC 0.889, CI 0.667–1, p = 0.011), leucine at day
+10 (Figure 3D, AUC 0.819, CI 0.542–1, p = 0.049), cystine at
day +100 (Figure 3E, AUC 0.778, CI 0.548–0.969, p = 0.055)
and isoleucine at day+100 (Figure 3F, AUC 0.764, CI 0.5–0.986,
p = 0.031). The composite panel ROC curve AUC was 0.896
(Figure 3G, CI 0.084–1), better than all other metabolites but
cystine at day+10.
We were not able to detect and quantify cysteine (the reduced
form of cystine) in our NMR platform analyzing the Brazilian
cohort samples. However, our GC-MS platform detected this
metabolite, whose concentrations were not statistically different
between the groups at any time (Supplementary Figures 3A,B,
p > 0.5 t-test) but numerically higher in cGVHD patients.
Two metabolites from BCAA metabolism were detected
and quantified by our NMR platform: 2-oxoisocaproate
(from leucine) and 3-methyl-2-oxovalerate (from isoleucine).
Both products were reduced in cGVHD patients mainly at
day +100 (Supplementary Figure 4). The 2-oxoisocaproate
concentration mean was 6.7µM (±0.8µM) in patients
without cGVHD and 4.9µM (±0.2µM) in cGVHD patients
(Supplementary Figure 4A, p = 0.140). The 3-methyl-2-
oxovalerate concentration mean was 5.8µM (±0.7µM) in
patients without cGVHD and 3.9µM (±0.3µM) in cGVHD
patients (Supplementary Figure 4B, p= 0.058).
We obtained 49 plasma samples collected around day +100
(98 ± 10) from the Danna-Farber Cancer Institute to validate
our findings. Again, none of the patients had clinical symptoms
of cGVHD or aGVHD before the blood sampling. All patients
had undergone allogeneic HSCT between January 2004 and
January 2013. Patient median age was 54 years (25–73 years),
25 patients (51%) were female and 24 (49%) were male
receptor female donors. Twenty-five (51%) selected patients
developed cGVHD and 24 (49%) patients were cGVHD-free
(29). Demographics and characteristics of the study population
are shown in Supplementary Table 2. These samples were
analyzed by LC/MS/MS in order to verify sulfur-containing
metabolites (cystine and cysteine) and BCAA concentrations
in a different cohort, from an outside transplantation center
and from a diverse ethnic population. We were not able
to replicate our findings for cystine in the North American
cohort (Figure 4A). However, contrary to the findings in the
Brazilian cohort (Supplementary Figure 3B), cysteine was found
to be increased in cGVHD patients from the North American
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FIGURE 3 | BCAA and cystine cluster cGVHD patients from patients without cGVHD. Clustering analyses and biomarker potential of 3 metabolites in 2 data points in
the discovery cohort. (A) Heatmap generated by cystine and leucine auto-scaled concentrations at day +10 and day +100 and isoleucine at day +100. (B–F)
Individual receiver operating characteristic (ROC) curves of metabolites and (G) composite ROC curve of the metabolite panel.
cohort (Supplementary Figure 3C, p = 0.007 t-test). Leucine
(Figure 4B, p = 0.020) and isoleucine (Figure 4C, p = 0.028)
significantly reduced in cGVHD patients by the t-test, while
valine was numerically lower but did not reach statistical
significance (Figure 4D, p= 0.160). ROC curve analysis of BCAA
concentrations (excluding valine) from the validation cohort
confirmed the ability of the score to predict cGVHD prior to
symptom development. The area under curve for leucine was
0.721 (CI 0.577–0.862, p = 0.0083), for isoleucine it was 0.719
(CI 0.564–0.852, p = 0.015) and for valine it was 0.643 (CI
0.472–0.792, p= 0.119).
Correlation analyses (Figure 5) showed that valine and
isoleucine concentrations are markedly correlated to leucine
concentration in both cohorts, using two different metabolomics
platforms (NMR and LC-MS/MS). The valine correlation
coefficient was 0.807 (p = 5.2E-05) in the Brazilian cohort and
0.796 (p= 7.8E-12) in theNorth American cohort. The isoleucine
correlation coefficient was 0.794 (p = 8.4E-05) and 0.741 (p
= 1.2E-09) in Brazilians and North Americans, respectively.
These results highlight the strong concentration correlation in
BCAA and corroborate differences in both groups (cGVHD-free
vs. cGVHD), indicating that if one BCAA changes, the others
are concordantly changed. Moreover, BCAA oxidation products
were also correlated to leucine in the Brazilian cohort: 0.582
(p = 0.011) and 0.561 (p = 0.015) for 2-oxoisocaproate and
3-methyl-2-oxovalerate, respectively. These oxidation products
were not measured in the North American cohort.
DISCUSSION
Graft vs. host disease (GVHD) is the leading cause of morbidity
and non-relapse mortality for long-term transplant survivors.(2–
5, 34) Immunosuppressive therapy currently employed to treat
cGVHD could be applied to prevent cGVHD(34), by delaying
planned immunosuppression (2). However, no biomarker panel
for cGVHD prediction is available, even with several approaches
that could be applied for biomarker prospection. It is known
thatmultisystemmetabolism is altered in cGVHD. Themetabolic
state of B cells is heightened in patients with active cGVHD
(35), as is the thiol/redox pathway in a GVHD experimental
model (22). Because metabolism is highly dynamic, metabolite
concentrations respond in a real-time fashion to reflect whole-
body homeostasis. In this scenario, metabolomics emerges as
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FIGURE 4 | Validation of potential biomarkers in North American patients at day +100 by LC-MS/MS. ROC curves and box-plot of concentrations (in arbitrary units)
are displayed. (A) Cystine, (B) Leucine, (C) Isoleucine, (D) Valine. Asterisk: student’s t-test p < 0.05.
FIGURE 5 | Correlation analysis to leucine at day +100. BCAA blood concentrations were well correlated to leucine concentration at (A) discovery cohort and
(B) validation cohort. Other correlated metabolites in both cohorts were tyrosine, histidine, arginine, ornithine, methionine, and asparagine, showing evidence of overall
consistence of metabolic profile measurements in both cohorts. 2-oxo-isocaproate and 3-methyl-2oxovalerate, BCAA degradation products, were also
well-correlated in the discovery cohort. These BCAA degradation products were not detected by LC-MS/MS platform on validation cohort.
a powerful approach with sensitivity and sensibility to detect
these dynamic changes. The hypothesis of this study is that
metabolomic profile changes in the blood precede the appearance
of cGVHD clinical symptoms as tissues are damaged. In order
to define when metabolomics changes would become evident,
several blood collection times, and metabolic profiling (by NMR
and GC-TOF-MS) were performed in the discovery cohort
(Brazilians) at day −10, day 0, day +10 and day +100. An
important aspect to highlight is that no patient had clinical
symptoms of cGVHD or aGVHD at sampling time (the same is
true for the validation cohort). Moreover, the validation cohort
(North Americans) is from another transplant center, from
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a diverse ethnic population, and the metabolite profiling was
performed by a distinct technique (LC/MS/MS), avoiding bias
from population and analytic methodology, respectively. For
the discovery cohort, sulfur-containing metabolite cystine and
branched chain amino acids (BCAA, leucine, and isoleucine)
were important to cluster cGVHD patients from patients without
cGVHD before clinical symptoms at day +10 and day +100.
We were able to replicate findings for BCAA in the validation
group at day +100 but not cystine. However, cysteine, another
sulfur-containing metabolite, was found increased in the North
American cohort.
Cystine is an oxidized dimeric form of cysteine and is involved
in T cell activation and proliferation. An excellent review on
this process can be reviewed in the work by Yan (36). Shortly:
naïve T cell activation and proliferation requires cysteine for
glutathione (GSH) synthesis in their intracellular space, but these
cells are unable to import cysteine, the less abundant amino
acid in the blood stream (36, 37). T cell activation also depends
on the immunological synapse with dendritic cells (DCs), and
DCs are able to import cystine, which is more abundant in
the blood stream than cysteine (36, 38). In the cytoplasm of
DC, cystine is converted to cysteine that is delivered in the
immunological synapse, producing a redox potential suitable for
T cell proliferation. Furthermore, T cells synthetize GSH, and
being activated can import this cysteine. Our data does not allow
us to explain whether cystine/cysteine is increased as a response
of immunological activity or whether this increase is related to
some intrinsic feature, unleashed after allogeneic HSCT, from
patients prone to developing cGVHD. In this regard, a study
with animal models and metabolomics showed accumulation of
plasma GSH precursors (cystathionine, total cysteine), and its
catabolite (cysteinylglycine) is probably due to impaired hepatic
GSH synthesis in early GVHD (22). The impaired GSH synthesis
in the liver during GVHD could make GSH precursors (as
cystine/cysteine) available for use by dendritic cells to activate
T-cells.
Three branched chain amino acids (BCAAs)—leucine,
isoleucine and valine—are among the nine essential
proteinogenic amino acids for humans (39). We were able
to identify and quantify these three amino acids in both
cohorts. We found the three BCAA concentrations reduced
in patients that developed cGVHD at day +10 and day +100
at discovery cohort and reduced at day +100 at validation
cohort (with different ranges and statistic significances).
Moreover, the degradation products of leucine and isoleucine
(2-oxoisocaproate and 3-methyl-2-oxovalerate) were also found
reduced in the cGVHD group in the discovery cohort at day
+100. In animal models for GVHD, BCAA plasma levels were
also reduced and strongly correlated with histopathological
changes in the liver of GVHD mice (22). However, we cannot
be sure that BCAAs are organ-specific biomarkers due to
multi-organ involvement in both cohorts. BCAAs are essential
to cells of the immune system. Uptake of BCAAs during
activation or mitotic stimulation is increased in T cells as
so in B cells (40, 41). BCAAs are also frequently associated
with benefits to body weight regulation and muscle protein
synthesis (42). These metabolites are considered anabolic signals
via mammalian target of rampamycin complex 1 (mTORC1)
activation and reduction of protein breakdown (42–44). These
same mechanisms (protein synthesis and mTORC1 activation)
can be enrolled for immune cell proliferation (41, 45). Our results
do not allow us to conclude that BCAA reduction in patients
pre-stage for cGVHD development is due to consumption by
immune cells and further activation/proliferation, consumption
by other tissues in order to recovery or avoid damage, or both,
because BCAAs are important for immune cell activation and
also for tissue maintenance.
In summary, we found two potential classes of predictive
biomarkers for cGVHD by using unbiased large-scale
metabolomic approaches in prospective and serial sampling
of blood serum/plasma. We demonstrated that BCAAs and
BCAA degradation product concentrations were reduced at day
+10 and day +100 post-HSCT in patients prone to developing
cGVHD. BCAAs were also reduced in a validation cohort at
day +100. We also found cystine concentrations higher in
patients prone to developing cGVHD at day +10 and day +100.
Cystine was not confirmed at the validation cohort but another
sulfur-containing metabolite, cysteine, was present. Strong
points of this project are the use of multi-platform metabolomics
approaches to prospect and confirm results in different ethnic
populations, avoiding technical and population bias. Further
experiments are necessary to access the clinical applicability of
BCAA as predictive biomarkers for cGVHD and our results
highlight multi-temporal and multivariate modeling as an
approach to increase the accuracy of predictions. Furthermore,
experimental models of GVHD and supplementation
with BCAA can shed light in new potential cGVHD
pre-emptive therapy.
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